Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery E, Lee JH, Liang W, Patel P, Quah C, Jurczak W. Ghia P, et al. Among authors: wach m. J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27. J Clin Oncol. 2020. PMID: 32459600 Clinical Trial.
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Montillo M, Illés Á, Robak T, Pristupa AS, Wach M, Egyed M, Delgado J, Jurczak W, Morschhauser F, Schuh A, Eradat H, Shreay S, Barrientos JC, Zelenetz AD. Montillo M, et al. Among authors: wach m. Health Qual Life Outcomes. 2019 Nov 15;17(1):173. doi: 10.1186/s12955-019-1232-8. Health Qual Life Outcomes. 2019. PMID: 31729982 Free PMC article. Clinical Trial.
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O. Holowiecki J, et al. Among authors: wach m. J Clin Oncol. 2012 Jul 10;30(20):2441-8. doi: 10.1200/JCO.2011.37.1286. Epub 2012 Apr 16. J Clin Oncol. 2012. PMID: 22508825 Clinical Trial.
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C. Jones JA, et al. Among authors: wach m. Lancet Haematol. 2017 Mar;4(3):e114-e126. doi: 10.1016/S2352-3026(17)30019-4. Lancet Haematol. 2017. PMID: 28257752 Clinical Trial.
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.
Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, Hellmann A, Kachel L, Holowiecki J, Gozdzik J, Hansz J, Avigdor A, Nagler A, Osowiecki M, Walewski J, Mensah P, Jurczak W, Skotnicki A, Sedzimirska M, Lange A, Sawicki W, Sulek K, Wach M, Dmoszynska A, Kus A, Robak T, Warzocha K. Czyz J, et al. Among authors: wach m. Ann Oncol. 2004 Aug;15(8):1222-30. doi: 10.1093/annonc/mdh304. Ann Oncol. 2004. PMID: 15277262 Free article.
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S; Polish Adult Leukemia Group. Wrzesień-Kuś A, et al. Among authors: wach m. Ann Hematol. 2005 Sep;84(9):557-64. doi: 10.1007/s00277-005-1046-0. Epub 2005 Apr 27. Ann Hematol. 2005. PMID: 15856358 Clinical Trial.
Central nervous involvement by chronic lymphocytic leukaemia.
Szczepanek D, Wąsik-Szczepanek E, Szymczyk A, Wach M, Cioch M, Podhorecka M, Grywalska E, Hus M. Szczepanek D, et al. Among authors: wach m. Neurol Neurochir Pol. 2018 Mar;52(2):228-234. doi: 10.1016/j.pjnns.2017.10.012. Epub 2017 Nov 1. Neurol Neurochir Pol. 2018. PMID: 29146406
The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.
Sacha T, Szczepanek E, Dumnicka P, Góra-Tybor J, Niesiobędzka-Krężel J, Prejzner W, Wasilewska E, Kłoczko J, Ciepłuch H, Makowska W, Patkowska E, Wasilewska J, Bober G, Kopera M, Wichary R, Kroll-Balcerzak R, Gromek T, Wach M, Rudkowska-Kazanowska A, Świniarska M, Paczkowska E, Biernat M, Joks M, Oller M, Kasza R, Kostyra A, Gil J, Grzybowska-Izydorczyk O. Sacha T, et al. Among authors: wach m. Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):405-415. doi: 10.1016/j.clml.2021.11.012. Epub 2021 Nov 20. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34933827 Free article.
High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group.
Czyz J, Hellmann A, Dziadziuszko R, Hansz J, Goździk J, Hołowiecki J, Stella-Hołowiecka B, Kachel Ł, Knopińska-Posłuszny W, Nagler A, Meder J, Walewski J, Lampka E, Sułek K, Sawicki W, Lange A, Forgacz K, Suchnicki K, Pacuszko T, Skotnicki A, Mensah P, Jurczak W, Kuliczkowski K, Wróbel T, Mazur G, Dmoszyńska A, Wach M, Robak T, Warzocha K. Czyz J, et al. Among authors: wach m. Bone Marrow Transplant. 2002 Jul;30(1):29-34. doi: 10.1038/sj.bmt.1703590. Bone Marrow Transplant. 2002. PMID: 12105774
85 results